MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

Yarilet Perez is an experienced multimedia journalist and fact-checker with a Master of Science in Journalism. She has worked in multiple cities covering breaking news, politics, education, and more.

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› This make-at-home spray ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...